CardiaLen
CardiaLen develops and commercializes pain-free cardioversion therapies for atrial fibrillation.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD93—139m (Dealroom.co estimates Oct 2018.)
Brooklyn Center Minnesota (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $337k | Debt | |
$1.0m | Debt | ||
$2.4m | Debt | ||
| N/A | $138k | Angel | |
| N/A | $3.4m | Series A | |
| N/A | $2.5m | Series A | |
| N/A | $1.6m | Debt | |
$1.5m | Series B | ||
| N/A | $1.8m | Early VC | |
$300k | Debt | ||
$17.0m | Series B | ||
N/A | Convertible | ||
| Total Funding | CAD35.9m | ||
Related Content
Recent News about CardiaLen
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.